S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.50
+1.82
+10.91%
CVKD · Cadrenal Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Cadrenal Therapeutics Inc (CVKD)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$1.02
-0.03
(-3.32%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.02
$1.02
$1.02
52-WEEK RANGE
$1.02
$0.82
$14.21
What's happening
- CVKD is down 3.32% today, trading at $1.02. — Live quote
- It's trading within 3% of its 52-week low ($0.82). (Finnhub fundamentals)
- Volume today (400) is well below its 3-month average of 360,880. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.14 actual vs. $-1.45 estimated (+21.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CVKD
-84.66%
vs S&P 500
-97.44%
1-YEAR RETURN
CVKD
-91.95%
vs S&P 500
-106.51%
6-MONTH RETURN
CVKD
-78.56%
3-MONTH RETURN
CVKD
-52.07%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.14
Est. $-1.45
BEAT +21.3%
2026-04-26 (Q1 2026)
$-1.04
Est. $-1.65
BEAT +37.1%
2026-01-26 (Q4 2025)
$-1.43
Est. $-1.19
MISS -20.3%
2025-10-26 (Q3 2025)
$-1.31
Est. $-1.56
BEAT +15.9%
Valuation Measures & Ratios
Enterprise Value4$1.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book72.34
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-406.38%
Return on Assets (ROA9)-273.79%
Avg Volume (3M)360,880
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $9.0M | $11.7M | $28.4M | $24.0M | $35.1M |
| P/E | -0.74 | -0.92 | -2.25 | -1.95 | -3.40 |
| Price/Book | 2.20 | 6.52 | 10.38 | 5.57 | 5.74 |
| ROE | -297.48% | -706.40% | -460.93% | -286.43% | -168.65% |
| ROA | -217.79% | -443.56% | -308.40% | -205.97% | -129.63% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short105,945
Change from Prior Settlement-10.82%
% of Float—
Days to Cover (Short Ratio)1.08
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -91.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CVKD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$3.3M | -$2.5M | -$2.7M | -$3.7M | -$3.9M | -$2.5M | -$2.5M | -$1.8M |
| Net income | -$3.3M | -$2.5M | -$2.7M | -$3.7M | -$3.8M | -$2.4M | -$2.4M | -$1.7M |
| EPS (diluted) | $-1.14 | $-1.04 | $-1.31 | $-1.87 | $-2.09 | $-2.18 | $-2.24 | $-1.56 |
| EPS (basic) | $-1.14 | $-1.04 | $-1.31 | $-1.87 | $-2.09 | $-2.18 | $-2.24 | $-1.56 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Aug '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $5.6M | $2.9M | $4.3M | $4.1M | — | $6.0M | $8.0M | $10.1M |
| Total liabilities | $1.5M | $1.1M | $1.6M | $1.4M | — | $1.7M | $1.8M | $2.7M |
| Stockholders' equity | $4.1M | $1.8M | $2.7M | $2.7M | — | $4.3M | $6.1M | $7.4M |
| Total current assets | $5.6M | $2.9M | $4.3M | $4.1M | — | $6.0M | $7.9M | $10.1M |
| Total current liabilities | $1.5M | $1.1M | $1.6M | $1.4M | — | $1.7M | $1.8M | $2.7M |
| Cash & equivalents | $2.4M | $2.3M | $4.0M | $3.9M | $5.0M | $5.6M | $7.3M | $10.0M |
| Property, plant & equipment | $2.7K | $4.6K | $5.2K | $5.7K | — | $4.3K | $4.7K | $6.9K |
| Other non-current assets | $2.2K | $2.2K | $2.2K | $2.2K | — | $2.2K | $3.8K | $3.8K |
| Accounts payable | $871.9K | $824.8K | $650.7K | $614.1K | — | $895.6K | $1.3M | $1.5M |
| Accrued liabilities | $625.3K | $240.1K | $937.3K | $738.5K | — | $783.9K | $561.8K | $1.2M |
| Common stock & paid-in capital | $3.1K | $2.5K | $2.3K | $2.1K | — | $2.0K | $1.9K | $1.8K |
| Retained earnings | -$44.8M | -$41.5M | -$39.0M | -$35.9M | — | -$33.2M | -$29.6M | -$25.7M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.2M | -$3.0M | -$2.6M | -$2.4M | -$3.0M | -$4.6M | -$1.8M | -$2.2M |
| Investing cash flow | $1.4K | — | $0 | -$1.9K | $0 | -$3.3K | -$6.5K | — |
| Financing cash flow | $2.3M | $1.3M | $2.7M | $648.4K | $1.3M | $2.0M | $7.5M | $1.5M |
| Free cash flow | — | — | -$2.6M | -$2.4M | -$3.0M | -$4.7M | -$1.8M | — |
| Capital expenditures | — | — | $0 | $1.9K | $0 | $3.3K | $6.5K | — |
| Share-based compensation | $672.1K | $252.4K | $325.1K | $473.4K | $592.6K | $548.8K | $763.2K | $300.0K |
| Change in accounts payable | $47.1K | $174.1K | $36.5K | -$281.5K | -$382.8K | -$224.1K | $1.0M | -$262.7K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating income | -$13.5M | -$11.0M | -$7.6M |
| Net income | -$13.2M | -$10.7M | -$8.4M |
| EPS (diluted) | $-6.64 | $-8.73 | $-9.29 |
| EPS (basic) | $-6.64 | $-8.73 | $-9.29 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $4.3M | $10.1M | $8.5M | $778.2K |
| Total liabilities | $1.6M | $2.7M | $826.9K | $6.3M |
| Stockholders' equity | $2.7M | $7.4M | $7.7M | -$5.6M |
| Total current assets | $4.3M | $10.1M | $8.5M | $727.6K |
| Total current liabilities | $1.6M | $2.7M | $826.9K | $1.3M |
| Cash & equivalents | $4.0M | $10.0M | $8.4M | $32.6K |
| Property, plant & equipment | $5.2K | $6.9K | $2.3K | $1.0K |
| Other non-current assets | $2.2K | $3.8K | $3.8K | $6.0K |
| Accounts payable | $650.7K | $1.5M | $167.3K | $404.9K |
| Accrued liabilities | $937.3K | $1.2M | $638.2K | $863.6K |
| Common stock & paid-in capital | $2.3K | $1.8K | $868 | $8.2K |
| Retained earnings | -$39.0M | -$25.7M | -$15.1M | -$6.7M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$12.6M | -$7.4M | -$3.5M |
| Investing cash flow | -$5.1K | -$6.5K | -$3.3K |
| Financing cash flow | $6.6M | $9.0M | $11.9M |
| Free cash flow | -$12.6M | -$7.4M | -$3.5M |
| Capital expenditures | $5.1K | $6.5K | $3.3K |
| Share-based compensation | $1.9M | $1.4M | $710.4K |
| Change in accounts payable | -$851.8K | $1.3M | -$237.6K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CVKD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-29 to 2026-06-29
Recent transactions
- Insiders have net sold 97,500 shares over the last 182 days, across 0 purchases and 22 sales.
- Most recent: Pham Quang X (Chairman and CEO) — Open market sale of 7,400 shares on 2026-06-29.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)97,500 sh(22 txns)
Net Shares-97,500
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Pham Quang X | Chairman and CEO | Open market sale | 2026-06-29 | 7,400 |
| Szot Matthew K | Chief Financial Officer | Open market sale | 2025-12-29 | 9,933 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-29 | Pham Quang X | Chairman and CEO | Open market sale | 7,400 | $3.03 |
| 2026-06-26 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 9,029 | $3.05 |
| 2026-06-25 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 2,127 | $3.00 |
| 2026-06-23 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 2,277 | $3.20 |
| 2026-06-22 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 9,167 | $3.55 |
| 2026-06-17 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 513 | $3.16 |
| 2026-06-16 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 3,613 | $3.18 |
| 2026-06-15 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 3,666 | $3.58 |
| 2026-06-12 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 12,996 | $3.94 |
| 2026-06-11 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 1,462 | $4.12 |
| 2026-06-10 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 3,500 | $4.21 |
| 2026-06-09 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 12,992 | $4.06 |
| 2026-06-08 | Pham Quang X | Chairman, CEO and Interim CFO | Open market sale | 5,893 | $4.38 |
| 2026-06-05 | Pham Quang X | CEO and Chairman | Open market sale | 2,064 | $4.42 |
| 2026-06-04 | Pham Quang X | CEO and Chairman | Open market sale | 3,898 | $4.41 |
| 2026-06-03 | Pham Quang X | CEO and Chairman | Open market sale | 2,323 | $4.26 |
| 2026-06-02 | Pham Quang X | CEO and Chairman | Open market sale | 349 | $4.46 |
| 2026-05-29 | Pham Quang X | CEO and Chairman | Open market sale | 303 | $5.01 |
| 2026-05-28 | Pham Quang X | CEO and Chairman | Open market sale | 2,989 | $4.93 |
| 2026-05-22 | Pham Quang X | CEO and Chairman | Open market sale | 1,165 | $5.69 |
| 2026-05-12 | Pham Quang X | CEO and Chairman | Open market sale | 3,298 | $5.28 |
| 2026-05-11 | Pham Quang X | CEO and Chairman | Open market sale | 6,476 | $5.76 |
| 2025-12-29 | Szot Matthew K | Chief Financial Officer | Open market sale | 9,933 | $6.97 |
| 2025-10-27 | Szot Matthew K | Chief Financial Officer | Open market sale | 1,800 | $13.99 |
| 2025-10-27 | Pham Quang X | CEO and Chairman | Open market sale | 1,315 | $13.99 |
| 2025-10-24 | Szot Matthew K | Chief Financial Officer | Open market sale | 1,800 | $13.99 |
| 2025-10-24 | Pham Quang X | CEO and Chairman | Open market sale | 1,129 | $14.03 |
| 2025-10-13 | Szot Matthew K | Chief Financial Officer | Open market sale | 1,800 | $14.07 |
| 2025-10-13 | Pham Quang X | CEO and Chairman | Open market sale | 1,800 | $14.15 |
| 2025-10-09 | Szot Matthew K | Chief Financial Officer | Open market sale | 1,693 | $13.99 |
| 2025-10-09 | Pham Quang X | CEO and Chairman | Open market sale | 1,800 | $14.02 |
| 2025-10-06 | Szot Matthew K | Chief Financial Officer | Open market sale | 107 | $13.99 |
| 2025-10-02 | Pham Quang X | CEO and Chairman | Open market sale | 500 | $14.13 |
| 2025-10-01 | Szot Matthew K | Chief Financial Officer | Open market sale | 1,700 | $13.99 |
| 2025-10-01 | Pham Quang X | CEO and Chairman | Open market sale | 881 | $14.01 |
| 2025-09-29 | Szot Matthew K | Chief Financial Officer | Open market sale | 100 | $14.00 |
| 2025-09-29 | Pham Quang X | CEO and Chairman | Open market sale | 419 | $14.01 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:48 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-07 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-24 | View on SEC.gov → |
| 2026-08-31 | 8-K | 2026-08-31 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-07-21 | 8-K | 2026-07-21 | View on SEC.gov → |
| 2026-07-17 | 8-K | 2026-07-14 | View on SEC.gov → |
Recent news
Headlines about CVKD (Cadrenal Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Cadrenal Therapeutics evaluating strategic options
Jacksonville Daily Record · 2026-10-15 -
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 2026-10-13 -
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Yahoo Finance · 2026-10-07 -
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Yahoo Finance · 2026-09-21 -
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Yahoo Finance · 2026-09-03 -
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Yahoo Finance · 2026-08-31 -
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
Yahoo Finance · 2026-08-31 -
Cadrenal Therapeutics GAAP EPS of -$1.14 beats by $0.02
Seeking Alpha · 2026-08-13
No headlines in this category right now — try “All”.